Strong Growth Propels Cantourage Group SE's Positive Outlook

Following significant regulatory changes in April, Cantourage Group SE has experienced remarkable sales growth throughout FY24. The company reported a notable 118% year-over-year increase in sales, reaching €51.4 million, surpassing its updated guidance range of €46-50 million. The fourth quarter alone accounted for €21.4 million, marking a 185% increase over the previous year. This growth was supported by de-bottlenecking efforts and increased supplier capacity.

Moreover, Cantourage achieved EBITDA profitability for the first time, with an expected 7.5% margin. The gross margin exceeded 37%, highlighting potential for improved profitability as sales volumes increase. Looking ahead to FY25, the company forecasts a 67% year-over-year growth, driven by expanded processing capacities, entry into the Polish market, and a telemedicine platform relaunch. Political uncertainties in Germany pose limited risks due to Cantourage's focus on the medical cannabis sector.